Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus’ multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development.
The next-generation of the Lens platform is built on over a decade of longitudinal real-world data and years of expertise translating that data into actionable evidence for biopharma. Lens combines one of the world's largest real-world multimodal datasets, high-performance AI computing, Tempus’ oncology foundation models, validated AI agents, and scientific workflows, all integrated into a single platform.
The platform was purpose-built to enable drug development teams to design better clinical trials, target patient subgroups faster, and generate critical evidence in a fraction of the time. Lens is commercially available today via lens.tempus.ai and is already utilized by a rapidly expanding user base, including 19 of the top 20 largest biopharma companies.
